Stock BGNE BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
164.4 USD +2.42% Intraday chart for BeiGene, Ltd. +5.05% -8.83%
04:31am Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up MT
May. 08 Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
MT
BeiGene's Q1 Loss Narrows as Revenue Rises
MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M
MT
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BU
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024
CI
Amgen Posts Higher 1Q Revenue, Swings to Loss
DJ
BeiGene : Financial Information - Form 8-K
PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BU
Sector Update: Health Care Stocks Rise in Afternoon Trading
MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise
MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer
MT
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BU
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
CI
BeiGene to Award Shares Worth $15 Million to 11 Directors
MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW